Premium
Drug “Pent‐Up” in Hollow Magnetic Prussian Blue Nanoparticles for NIR‐Induced Chemo‐Photothermal Tumor Therapy with Trimodal Imaging
Author(s) -
Li Jinghua,
Zhang Fengshou,
Hu Zhigang,
Song Weidong,
Li Guangda,
Liang Gaofeng,
Zhou Jun,
Li Ke,
Cao Yang,
Luo Zhong,
Cai Kaiyong
Publication year - 2017
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201700005
Subject(s) - photothermal therapy , prussian blue , materials science , in vivo , drug delivery , doxorubicin , magnetic resonance imaging , nanoparticle , nanotechnology , photothermal effect , biomedical engineering , biophysics , nuclear magnetic resonance , chemotherapy , chemistry , medicine , physics , microbiology and biotechnology , surgery , electrode , radiology , electrochemistry , biology
The study reports a biocompatible smart drug delivery system based on a doxorubicin (DOX) blending phase‐change material of 1‐pentadecanol loaded hollow magnetic Prussian blue nanoparticles, resulting in HMNP‐PB@Pent@DOX. The system possesses concentration‐dependent high thermogenesis (>50 °C) when applying a near‐infrared (NIR) laser irradiation only for 5 min. Furthermore, the system realizes near “zero release” of drug and is efficiently triggered by NIR for drug delivery in an “on” and “off” manner, thus inducing cell apoptosis in vitro and in vivo. Moreover, the system clearly indicates tumor site with trimodal imaging of magnetic resonance imaging, photoacoustic tomography imaging, and infrared thermal imaging. Furthermore, the system achieves efficient chemo‐photothermal combined tumor therapy in vivo with 808 nm laser irradiation for 5 min at 1.2 W cm −2 , revealing the good tumor inhibition effect comparing with those of chemotherapy or photothermal therapy alone. The system is also confirmed to be biocompatible in regard to the mortality rate.